The Hindu's page one story on GVK Biosciences and its disgruntled whistleblower quotes the company, the Commerce Ministry, the Indian Pharmaceutical Alliance and a drug controller here to rue the loss of reputation for the drug maker. The story suggests that the harm done to the company's reputation by international scrutiny and the ban on 700 drugs plays into the IPR tussle between the multinational drug companies and Indian generic drug makers. All fine except that you want to know, was there a basis for the charges about the clinical research? The fuller story on that aspect can be found here.